Christopher Newman
EditorChris is an editor at BioPharma Dive. He has been a journalist for more than 20 years, covering a wide range of topics including commodities, transportation, the U.S. Navy and Northern Virginia community news. Prior to joining Industry Dive, he was Argus Media’s senior editor for ferrous markets in Singapore, where he oversaw the company’s Asia coverage of steel and feedstocks iron ore, coking coal and scrap. He also covered thermal coal, railroads and environmental regulation for Argus in Washington, D.C. He was a reporter for the Manassas Journal Messenger, Potomac News, Fairfax Times and the Navy newsweekly Soundings. He has a B.A. in biology from the University of Virginia.
109 articles by Christopher Newman
-
Medicare has no surprises in planned registry for new Alzheimer’s drugs
June 23, 2023 -
FDA delays decision on GSK bone cancer drug acquired in $2B buyout
June 16, 2023 -
Pharmaceutical companies search for IRA response as they brace for drug pricing talks
June 15, 2023 -
FDA sets decision dates for Vertex, CRISPR gene editing drug
June 9, 2023 -
Merck sues to block Medicare negotiation of drug prices
June 6, 2023 -
Akero’s NASH therapy, paired with GLP-1 drugs, cuts liver fat in small study
June 5, 2023 -
Coherus sets steep discount for Humira copycat, plans direct sales
June 1, 2023 -
Medicare keeps limits on Alzheimer’s drug coverage, but loosens policy
June 1, 2023 -
FDA pauses PepGen’s plans to test muscle disease drug
May 31, 2023 -
Novo says oral version of obesity drug succeeds in large study
May 23, 2023 -
FDA advisers back maternal use of Pfizer RSV vaccine
May 19, 2023 -
Supreme Court sides with Sanofi, Regeneron in patent fight with Amgen
May 18, 2023 -
Gene therapy consortium targets eight rare diseases for clinical trials
May 16, 2023 -
UniQure sells royalty rights to hemophilia gene therapy
May 15, 2023 -
Sanofi, AstraZeneca study results add support for their RSV drug in infants
May 12, 2023 -
Magenta agrees to reverse merger with Dianthus after setbacks
May 3, 2023 -
FDA approves Seres’ microbiota drug for recurrent gut infection
April 26, 2023 -
Novartis trims 10% of drug pipeline in research cutback
April 25, 2023 -
After delay, Bluebird submits sickle cell gene therapy for FDA approval
April 24, 2023 -
Drugmakers take sides in Amgen, Regeneron fight over antibody patents
April 21, 2023 -
J&J leans on cancer drug sales to maintain first quarter growth
April 18, 2023 -
Manufacturing issues spur FDA to deny approval of Lilly colitis drug
April 14, 2023 -
Freeline cuts more jobs and halts Fabry gene therapy work
April 4, 2023 -
Vertex, CRISPR finish US filing for gene editing drug approval
April 3, 2023 -
5 FDA decisions to watch in the second quarter
April 3, 2023